TRI-50b
TRI-50b has been in phase II clinical trials by Trigen for the treatment of thrombosis. However, this research has been discontinued.
General Information
Update Date：2016-04-25
- Drug Name：
- TRI-50b
- Research Code：
- TRI-50b
- Trade Name：
- MOA：
- Thrombin inhibitor
- Indication：
- Thrombosis
- Status：
- Phase Ⅱ (Discontinued)
- Company：
- Trigen Holdings AG (Originator)
- Sales：
- ATC Code：
Chemical Structure
Update Date：2015-12-31
|
Molecular Weight | 607.55 | ||||||||||||
| Formula | C33H46BN3O7 | |||||||||||||
| CAS No. | 162854-81-1 (TRI-50b); | |||||||||||||
| Chemical Name | L-Prolinamide, N-[(phenylmethoxy)carbonyl]-D-phenylalanyl-N-[(1R)-4-methoxy-1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl]- (9CI) | |||||||||||||
| TRI-50b （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||